Details of the Drug Combinations

General Information of This Drug (ID: DMS2IUH)

• Drug Name: Valganciclovir (DMS2IUH)
• Synonyms: Cymeval; RS 79070; RO1079070/194; Valcyte (TN); Valganciclovir (INN); Valganciclovir (Oral); Valganciclovir [INN:BAN]; L-Valine, ester with ganciclovir; [2-[(2-amino-6-oxo-3H-purin-9-yl)methoxy]-3-hydroxypropyl] (2S)-2-amino-3-methylbutanoate; L-Valine, 2-((2-amino-1,6-dihydro-6-oxo-9H-purin-9-yl)methoxy)-3-hydroxypropyl ester; 5-Amino-3-[1-(hydroxymethyl)-2-(L-valyloxy)ethoxymethyl]-6,7-dihydro-3H-imidazo[4,5-d]pyrimidin-7-one

Indication

Virus infection; ICD 11: 1A24-1D9Z; Status: Approved [1]

• Therapeutic Class: Antiviral Agents
• Drug Type: Small molecular drug

List of Combinatorial Drugs (CBD) Containing This Drug

4 Clinical Trial Drug Combination(s) Consisting of This drug

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
ACER-001 + Valganciclovir	DCSC6QI	ACER-001	Gastric Cancer	[2]
Gemcitabine + Valganciclovir	DC4LFVQ	Gemcitabine	Nasopharyngeal Carcinoma	[3]
Zidovudine + Valganciclovir	DCASGIS	Zidovudine	Lymphoproliferative Disorder	[4]
Temozolomide + Valganciclovir	DCTRQYQ	Temozolomide	Glioblastoma Multiforme	[5]

References

• [1] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4716).
• [2] ClinicalTrials.gov (NCT00387530) Phenylbutyrate and Valganciclovir in Treating Patients With Relapsed or Refractory Epstein-Barr Virus-Positive Cancer
• [3] ClinicalTrials.gov (NCT02761291) Study of Cytolytic Viral Activation Therapy (CVAT) for Recurrent/Metastatic Nasopharyngeal Carcinoma
• [4] ClinicalTrials.gov (NCT00092222) Virotherapy and Natural History Study of KHSV-Associated Multricentric Castleman s Disease With Correlates of Disease Activity
• [5] ClinicalTrials.gov (NCT04116411) A Clinical Trial Evaluating the Efficacy of Valganciclovir in Glioblastoma Patients